| P50 | author | Stuart Cordwell | Q42323729 |
| P2093 | author name string | Alistair V G Edwards | |
| | Melanie Y White | |
| P2860 | cites work | An investigation into the human serum "interactome" | Q24294835 |
| | Functional proteomic analysis of protein kinase C epsilon signaling complexes in the normal heart and during cardioprotection | Q28141664 |
| | Pericardial fluid as a new material for clinical heart research | Q28200202 |
| | Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1 | Q28216249 |
| | Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome | Q28240315 |
| | The nitric oxide hypothesis of late preconditioning | Q28290101 |
| | Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury | Q28294888 |
| | Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium | Q28304462 |
| | Analysis of C-reactive protein and biochemical parameters in pericardial fluid | Q28468638 |
| | Modifications of myosin-regulatory light chain correlate with function of stunned myocardium. | Q30950972 |
| | A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. | Q33200417 |
| | Proteomics: from basic research to diagnostic application. A review of requirements & needs | Q33221190 |
| | Differential Expression of Heat Shock Proteins in Normal and Failing Human Hearts | Q59192159 |
| | Proteomic analysis of human vessels: Application to atherosclerotic plaques | Q59315364 |
| | Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database | Q33221802 |
| | Myocardial preconditioning and remote renal preconditioning--identifying a protective factor using proteomic methods? | Q33227021 |
| | Potential biomarkers for ischemic heart damage identified in mitochondrial proteins by comparative proteomics | Q33231214 |
| | Proteomic analysis reveals significant alternations of cardiac small heat shock protein expression in congestive heart failure | Q33234723 |
| | Proteomic analysis of rat aorta during atherosclerosis induced by high cholesterol diet and injection of vitamin D3. | Q33240147 |
| | Proteomic analysis of differential protein expression in atherosclerosis | Q33246067 |
| | When does a fingerprint constitute a diagnostic? | Q33257826 |
| | SELDI-TOF MS analysis of the Cardiac Troponin I forms present in plasma from patients with myocardial infarction | Q33262047 |
| | Human body fluid proteome analysis | Q33262623 |
| | Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry | Q33276995 |
| | p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia | Q33303032 |
| | Investigation of an albumin-enriched fraction of human serum and its albuminome | Q33701508 |
| | Biomarkers in acute cardiac disease: the present and the future | Q33997300 |
| | Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial | Q34275827 |
| | Genomics, proteomics and bioinformatics of human heart failure | Q34314129 |
| | Biomarkers: mining the biofluid proteome | Q34389937 |
| | Clinical implications of the new definition of myocardial infarction | Q34543932 |
| | Adenosinergic cardioprotection: multiple receptors, multiple pathways | Q34615807 |
| | Clinical proteomics: translating benchside promise into bedside reality | Q34810370 |
| | Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery | Q35599767 |
| | Inflammation and atherosclerosis: role of C-reactive protein in risk assessment | Q35721270 |
| | Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks | Q35749545 |
| | Rho-kinase is an important therapeutic target in cardiovascular medicine | Q36186014 |
| | Quest for novel cardiovascular biomarkers by proteomic analysis. | Q36219610 |
| | The amplified peptidome: the new treasure chest of candidate biomarkers | Q36370845 |
| | Recent developments in proteomics: implications for the study of cardiac hypertrophy and failure | Q36385628 |
| | Proteomics of the heart: unraveling disease | Q36399305 |
| | Survival kinases in ischemic preconditioning and postconditioning. | Q36424370 |
| | Proteomics and heart disease: identifying biomarkers of clinical utility | Q36445586 |
| | Serum biomarkers for heart failure | Q36477541 |
| | Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights | Q36491992 |
| | Developments in mass spectrometry for the analysis of complex protein mixtures | Q36505978 |
| | Biology of atherosclerotic plaques: what we are learning from proteomic analysis | Q36524948 |
| | Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice | Q36619158 |
| | Proteomics in cardiovascular surgery | Q36697186 |
| | Cardiovascular biomarkers: the state of the art in 2006. | Q36763214 |
| | Role of biomarkers in developing new therapies for vascular disease | Q36771454 |
| | Proteomics in atherothrombosis: a future perspective | Q36787244 |
| | Atherosclerosis: the path from genomics to therapeutics | Q36791618 |
| | The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes | Q36886445 |
| | Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. | Q36950451 |
| | Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future | Q36985811 |
| | Increased troponin levels in nonischemic cardiac conditions and noncardiac diseases | Q37076391 |
| | AMP-activated protein kinase conducts the ischemic stress response orchestra | Q37082296 |
| | Mass spectrometry and biomarker development | Q37339592 |
| | Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes | Q39671364 |
| | Clinical proteomics: A need to define the field and to begin to set adequate standards | Q40247421 |
| | In vitro biomarker discovery for atherosclerosis by proteomics | Q40501649 |
| | Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion | Q40919655 |
| | Preload induces troponin I degradation independently of myocardial ischemia | Q43586291 |
| | Preinfarct angina and exercise: yet another reason to stay physically active | Q43787201 |
| | Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode Na(+)-Ca(2+) exchange | Q43997280 |
| | Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits | Q44120093 |
| | Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice | Q44485950 |
| | Pericardial fluid level of heart-type cytoplasmic fatty acid-binding protein (H-FABP) is an indicator of severe myocardial ischemia | Q44771296 |
| | Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. | Q44907848 |
| | Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway | Q44970377 |
| | Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. | Q45036450 |
| | C-reactive protein levels and outcomes after statin therapy | Q45213511 |
| | Prognostic value of cardiac troponin T in patients with both acute and chronic stable congestive heart failure: comparison with atrial natriuretic peptide, brain natriuretic peptide and plasma norepinephrine | Q45226158 |
| | Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems | Q46413128 |
| | Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. | Q46606952 |
| | Myocardial subproteomic analysis of a constitutively active Rac1-expressing transgenic mouse with lethal myocardial hypertrophy | Q46697038 |
| | Postconditioning the human heart | Q46722557 |
| | PKCbeta modulates ischemia-reperfusion injury in the heart | Q46775223 |
| | Proteomic identification of endothelial proteins isolated in situ from atherosclerotic aorta via systemic perfusion | Q46903910 |
| | Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction | Q47269123 |
| | Detection of regional changes in protein levels in the in vivo canine model of acute heart failure following ischemia-reperfusion injury: functional proteomics studies | Q47279410 |
| | B-type natriuretic peptide in cardiovascular disease | Q48237778 |
| | An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. | Q50492023 |
| | Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. | Q51912505 |
| | Comparison of two-dimensional electrophoresis patterns of heat shock protein Hsp27 species in normal and cardiomyopathic hearts. | Q52975151 |
| | Could BNP screening of acute chest pain cases lead to safe earlier discharge of patients with non-cardiac causes? A pilot study. | Q53510158 |
| | Local delivery of PKCepsilon-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation. | Q53565571 |
| | Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion | Q57396518 |
| | Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore | Q57902814 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| | biomarker | Q864574 |
| P304 | page(s) | 1824-1837 | |
| P577 | publication date | 2008-07-30 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | The role of proteomics in clinical cardiovascular biomarker discovery | |
| P478 | volume | 7 | |